摘要
目的探讨格列齐特联合重组甘精胰岛素治疗2型糖尿病(T2DM)合并慢性肾功能不全的临床效果。方法选取2015年2月～2017年2月我院收治的80例T2DM合并慢性肾功能不全患者作为研究对象,根据治疗方案分为对照组和观察组,每组各40例。对照组服用格列齐特,观察组在对照组基础上加用重组甘精胰岛素,比较两组的治疗效果、血糖控制时间、达标时间、空腹血糖、餐后2 h血糖、低血糖发生率和不良反应发生率。结果观察组的治疗总有效率为92.5%,明显高于对照组的72.5%,差异有统计学意义(P<0.05);观察组的血糖控制时间、达标时间短于对照组,空腹血糖(FBG)和餐后2 h血糖低于对照组,差异有统计学意义(P<0.05);观察组的不良反应总发生率(10.0%)明显低于对照组(40.0%),差异有统计学意义(P<0.05)。结论给予T2DM伴随慢性肾功能不全患者格列齐特联合重组甘精胰岛素既能提高治疗效果,改善临床症状,又能减少不良反应,值得临床推广应用。
Objective To investigate the clinical effect of Gliclazide combined with Recombinant Insulin Glargine in the treatment of type 2 diabetes mellitus(T2 DM) complicated with chronic renal insufficiency. Methods Eighty T2 DM patients complicated with chronic renal insufficiency admitted to our hospital from February 2015 to February 2017 were selected as the subjects, and divided into control group and observation group according to different therapeutic regimens, with 40 cases in each group. In the control group, Gliclazide was used, while in the observation group, Recombinant Insulin Glargine was added on the basis of the control group. The therapeutic effect, blood glucose control and decrease to normal time, fasting blood glucose(FBG), 2-hour postprandial blood glucose, incidence of hypoglycemia, and incidence of adverse reactions were compared between the two groups. Results The total effectiveness rate of the observation group was 92.5%, which was much higher than that of the control group accounting for 72.5%,with a statistical difference(P<0.05). The blood glucose control and decrease to normal time in the observation group were shorter than those in the control group, and the FBG and 2-hour postprandial blood glucose of the observation group were lower than those of the control group, with statistical significance(P<0.05). The incidence of adverse reactions in the observation group(10.0%) was lower than that in the control group(40.0%), with statistical significance(P<0.05). Conclusion Glyceride combined with Recombinant Insulin Glargine in T2 DM patients with chronic renal insufficiency can improve the therapeutic effect, ameliorate clinical symptoms, and reduce adverse reactions. It is worthy of clinical application and promotion.
作者
刘细平
张弢
刘芸
LIU Xi-ping;ZHANG Tao;LIU Yun(Department of Internal Medicine,the Sixth People's Hospital of Jingdezhen City in Jiangxi Province,Jingdezhen 333000,China)
出处
《中国当代医药》
2018年第35期31-33,共3页
China Modern Medicine
关键词
格列齐特
重组甘精胰岛素
2型糖尿病
慢性肾功能不全
Gliclazide
Recombinant Insulin Glargine
Type 2 diabetes mellitus
Chronic renal insufficiency
